Abstracts tagged "ANCA"

Abstract Number: 1764 • 2018 ACR/ARHP Annual Meeting
The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are antagonistic ligands which bind with similar affinity to the extracellular domain of the tyrosine kinase with Ig-like and…
Abstract Number: 2732 • 2018 ACR/ARHP Annual Meeting
Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center
Mehmet Nedim Taş¹, Mete Kara¹, Sertaç Ketenci¹, Mete Pekdiker², Raika Durusoy³, Fikret Bademkıran⁴, Gokhan Keser⁵ and Kenan Aksu⁵, ¹Rheumatology, Ege University Medical Faculty, izmir, Turkey, ²Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, ³Public Health, Ege University Medical Faculty, izmir, Turkey, ⁴Neurology, Ege University Medical Faculty, izmir, Turkey, ⁵Rheumatology, Ege University Medical Faculty, Izmir, Turkey
Background/Purpose: Among many other organs and systems, ANCA-associated vasculitis (AAV) may also affect nervous system in up to more than half of patients, resulting in…
Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
John L. Niles¹, Peter A. Merkel², Lester Mertz³, Patricia B. Lehane⁴, Pooneh Pordeli⁵ and Félix Erblang⁶, ¹Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ⁶Hoffmann-La Roche Ltd., Basel, Switzerland
Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
Abstract Number: 2733 • 2018 ACR/ARHP Annual Meeting
From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associated Vasculitis
Kathleen Maksimowicz-McKinnon¹, Philip McCarthy², Sandeep Soman³ and John McKinnon³, ¹Rheumatology, Henry Ford Hospital, Detroit, MI, ²Michigan State University College of Osteopathic Medicine, East Lansing, MI, ³Henry Ford Hospital, Detroit, MI
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic inflammatory disorder frequently associated with significant disability and morbidity, which may lead to end-stage renal disease…
Abstract Number: 905 • 2018 ACR/ARHP Annual Meeting
Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroeder⁵, Brian Kabat⁵, Carol Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Philip Seo⁹, Robert F. Spiera¹⁰, Eugene William St. Clair¹¹, Fernando Fervenza¹², John H. Stone¹³, Paul A. Monach¹⁴, Ulrich Specks¹⁵ and Peter A. Merkel¹⁶, ¹Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medicine, Duke University Medical Center, Durham, NC, ¹²Nephrology, Mayo Clinic, Rochester, MN, ¹³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁵Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The deregulated overproduction of interleukin (IL)-6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases. We aimed to investigate serum IL-6 levels (sIL-6)…
Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Vanessa L. Kronzer¹, Daniel Larson², Cynthia S. Crowson^3,4, Kenneth J. Warrington⁵, Steven R. Ytterberg⁵, Ashima Makol⁴ and Matthew J. Koster⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
Abstract Number: 2734 • 2018 ACR/ARHP Annual Meeting
The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides
Mete Kara¹, Mehmet Nedim Taş¹, Raika Durusoy², Sertaç Ketenci¹, Mete Pekdiker³, Hande Ece Öz⁴, Gülay Aşçı⁵, Gokhan Keser⁶ and Kenan Aksu⁴, ¹Rheumatology, Ege University Medical Faculty, izmir, Turkey, ²Public Health, Ege University Medical Faculty, izmir, Turkey, ³Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, ⁴Rheumatology, Ege University Medical Faculty, İzmir, Turkey, ⁵Nephrology, Ege University Medical Faculty, İzmir, Turkey, ⁶Rheumatology, Ege University Medical Faculty, Izmir, Turkey
Background/Purpose: Elderly patients with ANCA associated vasculitides (AAV) seem to have clinical differences compared to younger patients. The aim of this study is to compare…
Abstract Number: 906 • 2018 ACR/ARHP Annual Meeting
Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵ and Peter A. Merkel^4,6, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:Although a link between gut microbiome and autoimmune diseases has been suggested, there is a gap in the understanding of the gut microbiome in ANCA-associated…
Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
Abstract Number: 2735 • 2018 ACR/ARHP Annual Meeting
Identifying ANCA-Associated Vasculitis Cases in Electronic Health Records Using Natural Language Processing
Zachary Wallace¹, John H. Stone² and Hyon K. Choi³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Epidemiologic studies of ANCA-associated vasculitis (AAV) using large data sets are often limited by the lack of validated definitions of AAV cases that can…
Abstract Number: 907 • 2018 ACR/ARHP Annual Meeting
Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Gwen Thompson¹, Marta Casal Moura², Darlene Nelson¹, Amber Hummel¹, Dieter E. Jenne³, Fernando Fervenza⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol Langford⁷, Joseph W. McCune⁸, Peter A. Merkel⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Robert F. Spiera¹², Eugene William St. Clair¹³, Steven R. Ytterberg¹⁴, John H. Stone¹⁵, William H. Robinson¹⁶, Yuan-Ping Pang¹ and Ulrich Specks¹⁷, ¹Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, ³Helmholtz Zentrum München, Munich, Germany, ⁴Nephrology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶University of Gronigen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Hospital for Special Surgery, New York, NY, ¹³Medicine, Duke University Medical Center, Durham, NC, ¹⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁶Stanford, Stanford, CA, ¹⁷Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Human-murine chimeric variants have been used to study specific epitope recognition by anti-neutrophil cytoplasmic antibodies (ANCAs) targeting proteinase 3 (PR3) in patients with ANCA-associated…
Abstract Number: 1958 • 2018 ACR/ARHP Annual Meeting
Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology
Marcia Friedman¹, Donseok Choi^1,2,3,4, Steven Planck^1,4, James T. Rosenbaum⁵ and Cailin Sibley¹, ¹Oregon Health & Science University, Portland, OR, ²OHSU-PSU School of Public Health, Portland, OR, ³Graduate School of Dentistry, Kyung Hee Universtiy, Seoul, Korea, Republic of (South), ⁴Casey Eye Institute, Portland, OR, ⁵Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: In recent years, several studies have characterized the gene expression signatures of different tissues affected by ANCA-associated vasculitis (AAV). The purpose of this study…
Abstract Number: 2737 • 2018 ACR/ARHP Annual Meeting
Opportunistic Infections in Medium and Small-Sized Vessel Vasculitis: Based on a Retrospectivestudy on 108 Patients
Raphaele Mestiri¹, Lafarge Antoine², Jean-Jacques Tudesq³, Marc Pineton de Chambrun⁴, Melanie Roriz⁵, Stéphane Bally⁶, Laurent Alric⁷, Damien Sène⁸, Thomas Quémeneur⁹, Cécile-Audrey Durel¹⁰, Brigitte Gilson¹¹, Alice Berezne¹², Anne-Marie Ruppert¹³, Raphaele Seror¹⁴, Philippe Guilpain¹⁵, Xavier Puéchal¹⁶, Luc Mouthon¹⁷, Loïc Guillevin¹⁶ and Benjamin Terrier¹⁸, ¹Internal Medicine, Cochin hospital, Paris, France, ²Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ³Internal Medicine, CHU Montpellier, Montpellier, France, ⁴Université Pierre et Marie Curie, Paris, France, ⁵Université Paris-Diderot, Paris, France, ⁶Nephrology, CH Chambery, Chambery, France, ⁷Internal Medicine, CHU Toulouse, Toulouse, France, ⁸Lariboisière Hospital, Paris Diderot University, Paris, France, ⁹Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ¹⁰Internal Medicine, Hôpital Edouard Herriot, lyon, France, ¹¹Internal Medicine, CH Verdun, Verdun, France, ¹²Internal Medicine, CH Annecy, Annecy, France, ¹³Pulmonology, Tenon hospital, Paris, France, ¹⁴Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ¹⁵Montpellier, Montpellier, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ¹⁸Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France
Background/Purpose: Overall survival has been markedly improved during the last decades in systemic vasculitis. In contrast, the use of immunosuppressive agents led to an increased…
Abstract Number: 1746 • 2018 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Hiromi Matsushita¹, Yoshioki Yamasaki², Yukiko Takakuwa³, Hidehiro Yamada⁴ and Kimito Kawahata³, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan
Background/Purpose: ANCA-associated vasculitis including microscopic polyangiitis (MPA) involves multiple organs including lungs. Clinical characteristics and impact on long-term survival in MPA patients with interstitial lung disease (ILD) have not…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].